Your browser doesn't support javascript.
loading
Immune escape of B-cell lymphoblastic leukemic cells through a lineage switch to acute myeloid leukemia.
Beldzinska-Gadek, Karolina; Zarzycka, Ewa; Pastuszak, Krzysztof; Borman, Katarzyna; Lewandowski, Krzysztof; Zaucha, Jan M; Prejzner, Witold.
Afiliação
  • Beldzinska-Gadek K; Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
  • Zarzycka E; First Doctoral School, Medical University of Gdansk, Gdansk, Poland.
  • Pastuszak K; Department of Hematology and Transplantology, Medical University of Gdansk, Gdansk, Poland.
  • Borman K; Department of Algorithms and System Modelling, Gdansk University of Technology, Gdansk, Poland.
  • Lewandowski K; Department of Translational Oncology, Medical University of Gdansk, Gdansk, Poland.
  • Zaucha JM; Centre of Biostatistics and Bioinformatics, Medical University of Gdansk, Gdansk, Poland.
  • Prejzner W; Intercollegiate Biotechnology Doctoral School, University of Gdansk and Medical University of Gdansk, Gdansk, Poland.
Leuk Lymphoma ; 65(9): 1292-1302, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38775354
ABSTRACT
Acute leukemia (AL) with a lineage switch (LS) is associated with poor prognosis. The predisposing factors of LS are unknown, apart from KMT2A rearrangements that have been reported to be associated with LS. Herein, we present two cases and review all 104 published cases to identify risk factors for LS. Most of the patients (75.5%) experienced a switch from the lymphoid phenotype to the myeloid phenotype. Eighteen patients (17.0%) experienced a transformation from acute myelogenous leukemia (AML) to acute lymphoblastic leukemia (ALL). Forty-nine (46.2%) patients carried a KMT2A rearrangement. Most of the cases involved LS from B-cell ALL (B-ALL) to AML (59.4%), and 49 patients (46.2%) carried KMT2A-rearrangements. Forty patients (37.7%) received lineage-specific immunotherapy. Our findings suggest that the prevalence of KMT2A rearrangements together with the lineage-specific immunotherapy may trigger LS, which supports the thesis of the existence of leukemia stem cells that are capable of lymphoid or myeloid differentiation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Linhagem da Célula / Proteína de Leucina Linfoide-Mieloide Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Polônia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Linhagem da Célula / Proteína de Leucina Linfoide-Mieloide Limite: Humans Idioma: En Revista: Leuk Lymphoma Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Polônia